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Abstract
Purpose In some cases of drug therapy, the available
evidence might be sufficient to extend the indications to
children without further clinical studies.
Methods We reviewed the available evidence for one of the
categories of drugs most frequently used off-label in
children: proton pump inhibitors (PPIs) used for the
treatment of gastroesophageal reflux disease (GERD). A
classification of the appropriateness of off-label use of PPIs
in children with GERD was also performed.
Results Of the five PPIs evaluated, only omeprazole has a
paediatric indication in Europe. Overall, 19 clinical trials
were retrieved and evaluated on the basis of pharmacoki-
netics, efficacy and safety data. The off-label use of
omeprazole, esomeprazole and lansoprazole in children
was evaluated as appropriate given the consistent available
evidence retrieved in literature.
Conclusion This study demonstrates the existence of a
large body of clinical evidence on the use of PPIs in
children. Regulatory agencies and ethical committees
should cope with this issue for ethical reasons to avoid
unnecessary trial replication.
Keywords Children . EuropeanMedicines Agency . Food
and Drug Administration . Gastroesophageal reflux disease .
Off-label . Proton pump inhibitors
Introduction
The use of unlicensed and off-label medicines in children is
widespread and has raised an increasing concern over the
last years. In the European Union (EU), 50% or more of the
medicines used in children have only been studied in
adults, and not necessarily for the same indication [1]. The
general lack of information and appropriate pharmaceutical
formulations for use in children may expose them to
unwanted adverse events or underdosing without the
expected efficacy. The need for more studies to obtain
paediatric information for medicines used in children is
now a matter of consensus on a global basis [2, 3]. The
awareness of off-label drug usage in the daily practice by
paediatricians and the need to identify specific off-label
clinical priorities in paediatrics have been documented in an
observational study conducted in 32 Italian Departments of
Paediatrics [4].
The policy implemented in the USA, culminating in the
Pediatric Research Equity Act of 2003, paved the way for
the new European legislation (the ‘Paediatric Regulation’),
which was adopted in January 2007 with the objective to
guide the development and authorisation of medicines for
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use in children aged 0–17 years [5–7].This legislation was
designed to better protect the health of children in the EU.
A Paediatric Committee was established within the Euro-
pean Medicines Agency (EMEA) with the intent to provide
scientific opinions on any development plan for paediatric
medicines. The Committee has identified therapeutic areas
where clinical studies on medicinal products for children
are considered both a priority and a prerequisite for
granting a paediatric indication [8].
A recent draft guidance has been issued by the U.S. Food
and Drug Administration (FDA) with the aim to effectively
manage the off-label phenomenon, enabling sponsors to
distribute publications about off-label use of approved drugs
to prescribers [9]. The potential pros and cons of this
approach have been strongly debated among the scientific
and regulatory community at the international level [10].
The current scenario on paediatric research and regula-
tion raises a new challenging question: is it always
necessary to perform additional clinical studies in children?
Our hypothesis is that, in some instances, the evidence
already available may be sufficient to extend the indications
to children without further clinical studies. This would
allow the translation of the existing evidence into clinical
practice, minimising regulatory hurdles and avoiding the
unethical replication of trials.
To test this hypothesis we reviewed the available
evidence for one of the categories of drugs most frequently
used off-label in children: proton pump inhibitors (PPIs) for
the treatment of gastroesophageal reflux disease (GERD).
The rationale for choosing PPIs stems from the following
considerations. The role of PPIs for the treatment of GERD
is identified as a paediatric need by the EMEA Paediatric
Committee [8]. However, although PPIs do not have an
indication for GERD in infants, clinical guidelines from the
North American Society for Pediatric Gastroenterology and
Nutrition address the use of PPIs for this age group [11].
Which line of action should be followed to better protect
paediatric patients? This question is of particular impor-
tance given the enormous increase in the use of PPIs in
infants for presumed GERD that has been documented (in
the 6 years from 1999 through 2004, there was a more than
sevenfold increase) and the largely inappropriate prescrip-
tion of PPIs in children presenting physiological GERD that
has been recently reported [12, 13].
The aim of the study was to review the clinical evidence
available in the published scientific literature concerning
the use of PPIs for the treatment of GERD in the paediatric
population in order to establish whether the absence of
authorised indications can be justified. An additional aim of
the study is to describe possible differences in the PPI-
approved indications for the treatment of GERD in the
paediatric population in the two largest regulatory agencies,
EMEA and FDA.
Methods
We performed a preliminary search to determine the
regulatory status of approved PPIs (omeprazole, esomepra-
zole, lansoprazole, rabeprazole and pantoprazole) in Europe
and the USA. The European summaries of product
characteristics (SPCs) were retrieved from the EUDRANET
database (http://ec.europa.eu/idabc/en/document/2291); the
U.S. patient information leaflets were retrieved from the
FDA website (www.fda.gov). The update of these docu-
ments was surveyed until June 2008. Information on
paediatric indications was abstracted from such documents,
and a comparison between Europe and the USA was then
carried out.
A comprehensive search on the MEDLINE and EMBASE
databases (January 1990–June 2008) was performed. All
clinical trials on the off-label use of PPIs for the treatment
of GERD in children (age 0–17 years) were considered
eligible for inclusion. For the purpose of this analysis, the
following parameters were assessed: study design, trial
information (country, centres), objectives (endpoints),
patients population, study duration, posology, formulation
and main findings (as reported by the authors). Given the
objective of the study, the analysis was restricted to the
trials conducted on patients’ age ranges not already
included in approved EU indications (e.g. for omeprazole,
only studies including children aged 0–2 years were
analysed).
We defined a priori a common data acquisition form to
be completed using the information collected from the
selected articles [14–32]. The information was used to
assess the available evidence on the pharmacokinetics (PK),
efficacy and safety of each drug. The safety profile of each
drug was evaluated through a comparison of adverse events
(AEs) for adults listed in SPC versus the AEs reported in
paediatric trials. A specific search on the MEDLINE and
EMBASE databases was performed in order to retrieve
safety data collected through reviews and observational
studies.
On the basis of the retrieved evidence, a classification of
the appropriateness of off-label use of PPIs in children with
GERD was performed. Each drug was ranked as having a
high, moderate or scarce appropriateness when adminis-
tered in children, depending on the fulfilment of three pre-
specified criteria. Specifically, a high appropriateness was
attributed to a compound when at least two efficacy trials
and two PK studies were retrieved and a comparable safety
profile versus adults was assessed. Lack of compliance with
one or more of the above-mentioned criteria leads to a
decrease in the ranking of appropriateness. For the
classification of appropriateness, strength of the endpoints
and robustness of the study designs have been also
considered as two additional criteria. The use of 24-h pH
210 Eur J Clin Pharmacol (2009) 65:209–216
monitoring and/or endoscopy, although surrogate end-
points, are considered to be acceptable predictors of
efficacy [33]. Double-blind randomised controlled trials
were considered the highest level of evidence for testing
medicines.
Results
The five PPIs currently marketed in the EU—omeprazole,
esomeprazole, lansoprazole, rabeprazole and pantoprazole—
were approved through a mutual recognition procedure. Of
these five PPIs, only omeprazole has a paediatric indication
(i.e. children aged ≥2 years). Esomeprazole, which is the
S-isomer of omeprazole, does not formally have any
paediatric indication, although the approved European
SPC contains information on posology in children under
the age of 12 years. At the end of June 2007 further
information on the posology in adolescents in terms of the
treatment of GERD was added for the pantoprazole SPC.
However, no changes were included in the therapeutic
indication section of the SPC.
The scenario in the USA appears to be different: three
out of five compounds (omeprazole, esomeprazole, lanso-
prazole) are currently authorised for children, although with
the exclusion of infant and neonate age groups (Table 1). It
is noteworthy that lansoprazole and esomeprazole are
approved for children aged 1–17 in the USA but not in
the EU. The most recently marketed PPIs (rabeprazole and
pantoprazole) are not indicated for use in children in the
USA nor in the EU.
Nineteen clinical trials testing PPIs in the treatment of
GERD in children were retrieved; these are summarised
in Table 2. Of these, eight were multicentre trials. More
than 40% of the trials evaluated were conducted in the
USA.
Findings on omeprazole consisted of six efficacy trials,
two also focussing on the PK profile. The study duration
ranged from 7 days to 3 months, and a total of 151 children
were enrolled; three studies were randomised controlled
trials (RCTs).
The evidence for lansoprazole consisted of six studies
(one was a RCT), testing efficacy and PK, with a study
duration ranging from 5 days to 3 months. Overall, 282
patients were enrolled. Four RCTs on esomeprazole were
retrieved: these were aimed at defining the PK, efficacy
and safety profile, with a total of 257 enrolled children.
The improvement of GERD symptoms was investigated
in two efficacy trials (one was a RCT) with pantoprazole.
The population enrolled consisted of 68 children with a
mean study duration of 1.5 month. Finally, for the latest
marketed PPI, rabeprazole, only one trial investigating
PK and safety was retrieved, with a population involving
24 children.
All PK studies were designed with the aim of determin-
ing doses. The posology adopted was homogeneous across
trials testing the same compound, and it was reported on a
milligram/kilogram per day basis, which is appropriate in
children. On the other hand, heterogeneity in terms of
formulations was observed across all of the evaluated trials.
It should also be highlighted that none of these studies was
designed as a comparative trial testing different PPIs. For
omeprazole and esomeprazole, evidence on efficacy and
PK emerged from at least three RCTs (in many cases, the
trials had a double-blind design).
Of note, in more than 70% of the efficacy trials, the
activity of each drug was evaluated on end points based on
the 24-h pH monitoring, often accompanied by an
endoscopy.
On the basis of the AEs reported in the trials included in
the analysis, all compounds presented a safety profile in
children that was comparable with one described in adults.
Only in the case of omeprazole were AEs of the respiratory
system reported more frequently in children aged 0–2 years
than in adults. This is also confirmed by recent literature
data [34]. Two reviews confirmed our findings in terms of
the comparability of the omeprazole, lansoprazole, esome-
prazole and pantoprazole safety profiles between children
and adults [33, 35]. A retrospective observational study that
evaluated the long-term safety and efficacy of omeprazole
and lansoprazole and involved 166 children reported that
PPIs are efficacious and well tolerated for continuous use
for as long as 11 years in children [36].
The off-label use of omeprazole, lansoprazole and
esomeprazole in children was evaluated as highly appro-
priate given the consistent available evidence on PK,
efficacy and safety (Table 3). Moderate appropriateness
was attributed to pantoprazole, due to the lack of PK data
and insufficient efficacy trials. Since no adequate evidence
Table 1 Approved indications of PPIs for the treatment of GERD in
the European Union and the USA
Drug EU indication US indication
Omeprazole GERD ≥2 years GERD 2–16 years
Esomeprazole Not authorised in
childrena
GERD 1–17 years
Lansoprazole Not authorised in
children
GERD 1–17 years








PPI, Proton pump inhibitors; GERD, gastroesophageal reflux disease
a Information on posology in adolescents (≥12 years) with GERD is
available in the summaries of product characteristics (SPC)
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was available for rabeprazole, its off-label use was
considered to be scarcely appropriate in children.
Discussion and conclusions
Of the five authorized PPIs in Europe only one,
omeprazole, has a paediatric indication. Consequently,
any use of PPIs for the treatment of GERD in patients
under the age of 2 years and the paediatric use of all
PPIs but omeprazole in patients between 2 and 17 years
are to be considered off-label in the EU. Our findings
also highlight the discrepancies between regulatory
agencies in terms of approved indications (i.e. PPIs for
the treatment of GERD in children). Wide discrepancies
between the EU and the USA were observed regarding
paediatric indications of three compounds, esomeprazole,
lansoprazole and pantoprazole. Whereas esomeprazole
and lansoprazole are only authorised by the FDA for
the treatment of GERD in children aged 1–17 years,
pantoprazole was recently reviewed in terms of children
posology only in the EU. This heterogeneity could be
overcome through the integrated efforts of different
regulatory authorities to share more information on the
regulatory decision-making process for paediatric drugs.
In addition, the incoherence between the posology
section and the clinical indication section of the same
SPC represents potentially misleading information for
prescribers.
According to our analysis, omeprazole, esomeprazole
and lansoprazole showed a satisfying level of clinical
evidence for paediatric use in the age ranges that are not
covered by a formal indication. Those compounds fulfilled
all of the criteria for a high appropriateness for administra-
tion in children.
A robust clinical data package, i.e. at least two efficacy
and two PK trials, and a comparable safety profile between
children and adults represent the required level of evidence
for avoiding that further paediatric trials are carried out
solely for registration and regulatory purposes. This is also
in line with the EMEA recommendations on clinical drug
development [37–39]. Analysing the available clinical data
prior to conducting further trials could be one approach for
avoiding the well-known practical and ethical problems
related to testing drugs in children. Even when the clinical
data package is not robust enough, as in the case of
pantoprazole, further testing could be limited only to the
missing information.
The case of omeprazole and rabeprazole, respectively
evaluated as highly and scarcely appropriate in children,
raises further research questions and ethical concerns. In
fact, the amount of information available for omeprazole
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same class, such as rabeprazole, useless and unethical
unless within comparative trials.
It is often reported that the lack of clinical trials in
children can be attributable to ethical, methodological and
financial issues. However, our analysis shows a different
scenario: although there is a consistent amount of published
paediatric trials for this specific condition, the use of PPIs
for GERD is still considered off-label. Our study also
showed the existence of a large amount of clinical evidence
on the use of PPIs in children and, therefore, that
performing trials in children is feasible.
We believe that the evaluation we carried out on the
appropriateness of off-label use of PPIs in children could be
easily extended to other classes of drugs or other special
populations. Similar analyses could be helpful for prescrib-
ers. This would at least allow a more evidence-based
approach to off-label prescribing. Moreover, this model
could help regulatory authorities identify research priorities
for a specific compound (e.g. a further PK study) and
require specific mandatory studies for those important
questions of efficacy or safety which still remain unre-
solved. However, most of the retrieved trials were not RCTs
and were based on small sample sizes. Regulatory bodies
should promote and support the conducting of few large
and well-designed trials instead of a multiplicity of small
trials with weak methodology. This could contribute to a
better protection of the patients from the potential hazards
of the off-label use of drugs.
There are two main limitations to our analysis. Firstly, the
evaluation of safety in children for each compound was based
on information retrieved in published studies (i.e. clinical
trials, reviews, observational studies). Given the small number
of patients enrolled in clinical trials, only the more frequent
events could have been observed and reported in each trial.
Secondly, we identified the heterogeneity of formulations
used as a potential limitation. However, such heterogeneity is
a common problem in studies involving children.
In conclusion, the use of medicines that have not been
studied and assessed fully in children is a common situation
in Europe as well as the rest of the world.
This studywas prepared from a public health perspective. A
review of the literature with the aim of searching out published
findings can be a useful tool for regulators and policy-makers
within the framework of granting children simplified access to
medicines. Translating clinical evidence into clinical practice
and health-care decision-making could be a useful strategy to
fill the gap between regulatory bodies and patients, thereby
ensuring an equal and quicker access to medicines.
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